scholarly journals Exploring Prostate Cancer Patients’ Interest and Preferences for Receiving Genetic Risk Information About Cancer Aggressiveness

2020 ◽  
Vol 14 (3) ◽  
pp. 155798832091962
Author(s):  
Siddhartha Roy ◽  
Clement K. Gwede ◽  
Teri L. Malo ◽  
Courtney L. Scherr ◽  
Selina Radlein ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Treatment Option ◽  
Genetic Risk ◽  
Risk Information ◽  
Future Research ◽  
Aggressive Prostate Cancer ◽  
Genetic Risk Information ◽  
Cancer Aggressiveness ◽  
To Receive

The number of cases of aggressive prostate cancer is increasing. Differentiating between aggressive and indolent cases has resulted in increased difficulty for the physician and patient to decide on the best treatment option. Due to this challenge, efforts are underway to profile genetic risk for prostate cancer aggressiveness, which may help physicians and patients at risk for developing aggressive prostate cancer to select an appropriate treatment option. This study explores patients’ interest in receiving genetic results, preference for how genetic risk information should be communicated, and willingness to share results with adult male first-degree relatives (FDRs). A nine-item survey was adapted to assess their beliefs and attitudes about genetic testing for prostate cancer aggressiveness. In addition, participants ( n = 50) responded to hypothetical scenarios and questions associated with perceived importance of risk disclosure, preferences for receiving genetic risk information, and sharing of results with FDRs. As the hypothetical risk estimate for aggressive prostate cancer increased, patients’ willingness to receive genetic risk information increased. This study found that most patients preferred receiving genetic risk education in the form of a DVD (76%), one-page informational sheet (75%), or educational booklet (70%). Almost all patients (98%) reported that they would be willing to share their test results with FDRs. The results of this study highlight prostate cancer patients’ desire to receive and share genetic risk information. Future research should focus on assessing the long-term benefits of receiving genetic information for prostate cancer patients and implications of sharing this information with FDRs.

scholarly journals Factors affecting breast cancer patients' need for genetic risk information: From information insufficiency to information need

2019 ◽  
Vol 28 (3) ◽  
pp. 543-557 ◽  
Author(s):  
Soo Jung Hong ◽  
Barbara Biesecker ◽  
Jennifer Ivanovich ◽  
Melody Goodman ◽  
Kimberly A. Kaphingst
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Genetic Risk ◽  
Risk Information ◽  
Breast Cancer Patients ◽  
Information Need ◽  
Factors Affecting ◽  
Genetic Risk Information

scholarly journals The role of current affect, anticipated affect and spontaneous self-affirmation in decisions to receive self-threatening genetic risk information

2014 ◽  
Vol 29 (8) ◽  
pp. 1456-1465 ◽  
Author(s):  
Rebecca A. Ferrer ◽  
Jennifer M. Taber ◽  
William M. P. Klein ◽  
Peter R. Harris ◽  
Katie L. Lewis ◽  
...  
Keyword(s):  
Genetic Risk ◽  
Risk Information ◽  
Genetic Risk Information ◽  
Anticipated Affect ◽  
To Receive

scholarly journals Genome-wide association study of germline copy number variations reveals an association with prostate cancer aggressiveness

Mutagenesis ◽  
2020 ◽  
Vol 35 (3) ◽  
pp. 283-290
Author(s):  
Stefanie Brezina ◽  
Moritz Feigl ◽  
Tanja Gumpenberger ◽  
Ricarda Staudinger ◽  
Andreas Baierl ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Risk Stratification ◽  
Cancer Patients ◽  
Copy Number ◽  
Copy Number Variations ◽  
Prostatic Hyperplasia ◽  
Aggressive Prostate Cancer ◽  
Genome Wide ◽  
Cancer Aggressiveness

Abstract Prostate cancer is a major health burden, being the second most commonly diagnosed malignancy in men worldwide. Overtreatment represents a major problem in prostate cancer therapy, leading to significant long-term quality-of-life effects for patients and a broad socio-ecological burden. Biomarkers that could facilitate risk stratification of prostate cancer aggressiveness at the time of diagnosis may help to guide clinical treatment decisions and reduce overtreatment. Previous research on genetic variations in prostate cancer has shown that germline copy number variations as well as somatic copy number alterations are commonly present in cancer patients, altering a greater portion of the cancer genome than any other type of genetic variation. To investigate the effect of germline copy number variations on cancer aggressiveness we have compared genome-wide screening data from genomic DNA isolated from the blood of 120 patients with aggressive prostate cancer, 231 patients with non-aggressive prostate cancer and 87 controls with benign prostatic hyperplasia from the Prostate Cancer Study of Austria biobank using the Affymetrix SNP 6.0 array. We could show that patients with an aggressive form of prostate cancer had a higher frequency of copy number variations [mean count of copy number segments (CNS) = 12.9, median count of CNS = 9] compared to patients with non-aggressive prostate cancer (mean count of CNS = 10.4, median count of CNS = 8) or control patients diagnosed with benign prostatic hyperplasia (mean count of CNS = 9.3, median count of CNS = 8). In general, we observed that copy number gain is a rarer event, compared to copy number loss within all three patient groups. Furthermore, we could show a significant effect of copy number losses located on chromosomes 8, 9 and 10 on prostate cancer aggressiveness (P = 0.040, P = 0.037 and P = 0.005, respectively). Applying a cross-validation analysis yielded an area under the curve of 0.63. Our study reports promising findings suggesting that copy number losses might play an important role in the establishment of novel biomarkers to predict prostate cancer aggressiveness at the time of diagnosis. Such markers could be used to facilitate risk stratification to reduce overtreatment of prostate cancer patients.

C78: Genetic studies on Romanian prostate cancer patients confirm genetic risk variants for prostate cancer

2014 ◽  
Vol 13 (6) ◽  
pp. e1266
Author(s):  
A.S.C. Rascu ◽  
V. Jinga ◽  
M. Dumitrache ◽  
M. Merticariu ◽  
R. Petca ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Genetic Risk ◽  
Genetic Studies ◽  
Risk Variants ◽  
Genetic Risk Variants

scholarly journals The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat

2021 ◽  
Vol 15 (12) ◽  
Author(s):  
Roderick Clark ◽  
Miran Kenk ◽  
Kristen McAlpine ◽  
Emily Thain ◽  
Kirsten M. Farncombe ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Testing ◽  
Genetic Risk ◽  
Genetic Disorders ◽  
Future Research ◽  
Policy Action ◽  
Cancer Centre ◽  
Pathogenic Variants ◽  
Increased Risk ◽  
International Experts

Introduction: Prostate cancer is a significant cause of cancer mortality. It has been well-established that certain germline pathogenic variants confer both an increased risk of being diagnosed with prostate cancer and dying of prostate cancer.1 There are exciting developments in both the availability of genetic testing and opportunities for improved treatment of patients. On August 19, 2020, the Princess Margaret Cancer Centre in Toronto, Ontario, hosted a virtual retreat, bringing together international experts in urology, medical oncology, radiation oncology, medical genetics, and translational research, as well as a patient representative. We are pleased to provide this manuscript as a review of those proceedings for Canadian clinicians. Recommendations: We drafted several recommendations for future research and policy action based on this meeting: 1) Need for increased access to funding for germline testing for the common genetic disorders associated with increased risk of prostate cancer. 2) A need for increased research into identifying genetic factors influencing risk stratification, treatment response, and outcomes of prostate cancer within Canadian populations at increased genetic risk for prostate cancer. 3) Need for increased awareness about genetic risk factors among the Canadian public. 4) Need for research on patient perspectives and psychosocial outcomes in individuals identified to be at increased genetic risk of prostate cancer. 5) We support the creation of specialized multidisciplinary clinics that specialize in tailored care for patients at increased genetic risk of prostate cancer.

scholarly journals Implications of genetic risk information in families with a high density of bipolar disorder: an exploratory study

2005 ◽  
Vol 60 (1) ◽  
pp. 109-118 ◽  
Author(s):  
Bettina Meiser ◽  
Philip B. Mitchell ◽  
H. McGirr ◽  
M. Van Herten ◽  
Peter R. Schofield
Keyword(s):  
Bipolar Disorder ◽  
Genetic Risk ◽  
Exploratory Study ◽  
Risk Information ◽  
High Density ◽  
Genetic Risk Information

scholarly journals Let the Individuals Directly Concerned Decide: A Solution to Tragic Choices in Genetic Risk Information

2016 ◽  
Vol 19 (5) ◽  
pp. 307-313 ◽  
Author(s):  
Serena Oliveri ◽  
Gabriella Pravettoni ◽  
Chiara Fioretti ◽  
Mats G. Hansson
Keyword(s):  
Genetic Risk ◽  
Risk Information ◽  
Genetic Risk Information

scholarly journals Adolescents' opinions about genetic risk information, prenatal diagnosis, and pregnancy termination

1995 ◽  
Vol 32 (10) ◽  
pp. 799-804 ◽  
Author(s):  
M. Decruyenaere ◽  
G. Evers-Kiebooms ◽  
M. Welkenhuysen ◽  
J. Bande-Knops ◽  
V. V. Gerven ◽  
...  
Keyword(s):  
Prenatal Diagnosis ◽  
Genetic Risk ◽  
Pregnancy Termination ◽  
Risk Information ◽  
Genetic Risk Information

Among men with low-grade prostate cancer on prostate biopsy, the 4Kscore to predict prostate cancer aggressiveness at prostatectomy.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 65-65
Author(s):  
Bruno Nahar ◽  
Sanoj Punnen ◽  
Stephen M Zappala ◽  
Daniel Sjoberg ◽  
Dipen Parekh
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Radical Prostatectomy ◽  
Prostate Biopsy ◽  
The United States ◽  
Low Grade ◽  
Surgical Specimen ◽  
Aggressive Prostate Cancer ◽  
Free Psa ◽  
Cancer Aggressiveness

65 Background: Most men diagnosed with prostate cancer in the United States have low-grade tumors. While many of these men are good candidates for active surveillance, a proportion will have a bad outcome due to the presence of a more aggressive prostate cancer that was missed on initial biopsy. A recent study confirmed the 4Kscore accurately predicts the likelihood of aggressive cancer on prostate biopsy. We analyzed if the 4Kscore could predict the presence of more significant cancer in men with low-grade tumors on the diagnostic biopsy. Methods: A recent prospective validation of the 4Kscore was conducted at 26 sites throughout the United States. We selected men who were found to have low-grade (Gleason 6) cancer on biopsy for this analysis. The 4Kscore calculates the risk of aggressive prostate cancer on prostate biopsy by a blood test that measures levels of four kallikrein biomarkers (total PSA, free PSA, intact PSA, and human kallikrein-2) plus age, DRE findings, and prior biopsy status. We investigated whether the 4Kscore was associated with more significant cancer among men found to have Gleason 6 cancer on prostate biopsy. We also looked at a subset of these men who underwent radical prostatectomy to see if the 4Kscore was associated with prostate cancer being upgraded in the surgical specimen. Results: Among the 1,312 men enrolled in this trial, 306 men were found to have Gleason 6 cancer on prostate biopsy. The 4Kscore was significantly associated with the number of positive cores (p=0.001) and the millimeters of cancer seen (p=0.0002), with higher 4Kscores relating to more extensive cancer present on biopsy. In the subpopulation of 51 men who underwent radical prostatectomy, the median 4Kscore was significantly higher among men who had an upgrade to Gleason 7 or higher [15% (8,25)] compared to men who did not experience an upgrade [7% (4,14)] (p=0.032) in their final pathology. Conclusions: Among men with Gleason 6 prostate cancer on biopsy, the 4Kscore was associated with the prostate cancer being upgraded in the surgical specimen at radical prostatectomy. The 4Kscore test may facilitate the selection of men who can be observed versus those who should undergo immediate treatment.

Sign in / Sign up

Export Citation Format

Share Document